HYFT
MindWalk Holdings Corp.·Healthcare
1.07
4.464%(−0.05)
Market ClosedLast Updated: — ET
52W L: $0.4052W H: $3.25
HYFT NEWS
seekingalpha.com
Mar 12
MindWalk Holdings Corp. (HYFT) Q3 2026 Earnings Call Transcript
MindWalk Holdings Corp. (HYFT) Q3 2026 Earnings Call Transcript
zacks.com
Mar 12
MindWalk Holdings Corp. (HYFT) Reports Q3 Loss, Lags Revenue Estimates
MindWalk Holdings Corp. (HYFT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.06 per share a year ago.
businesswire.com
Mar 12
MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results
AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (Nasdaq: HYFT), a Bio-Native AI company focused on biologics discovery and AI-driven drug development, today reported financial results for the third quarter of fiscal year 2026, ended January 31, 2026. MindWalk will host its Q3 Fiscal 2026 Earnings Call today at 10:30 AM Eastern Time. Revenue for Q3 was $4.2 million, a 52 percent increase from $2.7 million in Q3 fiscal 2025, marking MindWalk's third consecutive quarter of year-over-year r.
defenseworld.net
Mar 10
Financial Survey: MindWalk (NASDAQ:HYFT) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT)
MindWalk (NASDAQ: HYFT - Get Free Report) and Calliditas Therapeutics AB (publ) (NASDAQ: CALT - Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk. Risk and Volatility MindWalk has a
businesswire.com
Mar 6
MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era
AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (NASDAQ: HYFT), a bio-native AI company, today announced B Cell Llama™, a platform for the discovery of VHH nanobodies: the single-domain antibody fragments increasingly recognized as the ideal molecular building blocks for bispecific antibodies, multispecific therapeutics, and CAR-T cell therapies. Bispecific antibody sales alone are projected to reach US$50 billion by 2030, with the broader cell therapy market adding tens of billions mor.
businesswire.com
Mar 2
MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026
AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced that it will report financial results for the third quarter of fiscal year 2026 and host a conference call on Thursday, March 12, 2026, at 10:30 AM Eastern Time. Financial results will be issued in a press release prior to the call, which will include a management presentation followed by a question-and-answer session.
